An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome

@article{Brandt2009AnEP,
  title={An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome},
  author={Lawrence J Brandt and William D. Chey and Amy E. Foxx-Orenstein and Lawrence R. Schiller and Philip Schoenfeld and Brennan M. R. Spiegel and Nicholas J. Talley and Eamonn M M Quigley},
  journal={The American Journal of Gastroenterology},
  year={2009},
  volume={104},
  pages={S1-S35}
}
IBS is characterized by abdominal discomfort associated with altered bowel function; structural and biochemical abnormalities are absent. e pathophysiology of IBS is multifactorial and of intense recent interest, largely because of the possibility of developing targeted therapies. As IBS is one of the most common disorders managed by gastroenterologists and primary care physicians, this monograph was developed to educate physicians about its epidemiology, diagnostic approach, and treatments. e… 

Assessment of Consensus-Based Pharmacological Therapies in Irritable Bowel Syndrome

TLDR
There is a need for new drugs in the setting of pharmacological therapy for the IBS and a new medical approach should include both novel and traditional drugs in order to reach to a desirable outcome for patients and improve their quality of life.

Irritable bowel syndrome: a clinical review.

TLDR
The existing evidence on epidemiology, pathophysiology, and diagnosis of IBS is summarized to provide practical treatment recommendations for generalists and specialists according to the best available evidence.

Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.

TLDR
A narrative review covers the spectrum of available drugs and their mechanisms of action, as well as the efficacy and safety profiles of each as determined in relevant clinical trials that have investigated treatment options for IBS-C and chronic constipation.

An update on irritable bowel syndrome: from diagnosis to emerging therapies

TLDR
Novel and emerging therapies that are based upon the evolving understanding of the pathophysiology of IBS hold significant promise and for the first time there are potential therapies that may alter the natural history of this disorder.

[Diagnosis of irritable bowel syndrome: a systematic review].

TLDR
Recommendations for the diagnosis and treatment of IBS patients have been designed to give a favored effect on the Department of Gastroenterology's overall performance to establish the strategy of Ibs treatment, which is very necessary for the current clinical practice.

Irritable bowel syndrome: a clinical review.

  • R. Soares
  • Medicine
    World journal of gastroenterology
  • 2014
TLDR
There is still no clinical evidence to recommend the use of biomarkers in blood to diagnose IBS, however, a number of different changes in IBS patients were demonstrated in recent years, some of which can be used in the future as a diagnostic support.

Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.

  • L. Saha
  • Medicine
    World journal of gastroenterology
  • 2014
TLDR
The aim of this review is to provide a comprehensive evidence-based review of the diagnosis, pathogenesis and treatment of IBS to guide clinicians diagnosing and treating their patients.

[Irritable Bowel Syndrome].

  • J. KimS. Jee
  • Medicine
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • 2019
TLDR
The KSNM defines IBS as a chronic, recurrent symptom complex that includes abdominal pain or discomfort, changes in bowel habits, and bloating for at least 6 months, which is somewhat broader than the previous definition.

New pharmacological treatment options for irritable bowel syndrome with constipation

TLDR
This review focuses on the pharmacology, efficacy, safety, and future of prucalopride, YKP-10811, DSP-6952, dexloxiglumide, linaclotide, plecanatide, tenapanor, and elobixibat.

A REVIEW ON RECENT APPROACHES IN TREATMENT OF IRRITABLE BOWEL SYNDROME

TLDR
A systematic overview of recently approved or novel medications that show promise for the treatment of irritable bowel syndrome is provided.
...

References

SHOWING 1-10 OF 110 REFERENCES

Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria

TLDR
Examination of screening tests in 1452 patients with an established history of IBS revealed an incidence of lactose malabsorption comparable to that in the general U.S. population and a low incidence of thyroid dysfunction, ova and parasite infestation, or colonic pathology.

Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

TLDR
Multivariate statistical analyses suggest that gastrointestinal disorders, psychiatric disorders, and nongastrointestinal somatic disorders are distinct disorders and not manifestations of a common somatization disorder, but their strong comorbidity suggests a common feature important to their expression, which is most likely psychological.

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

TLDR
Individual symptoms have limited accuracy for diagnosing IBS in patients referred with lower gastrointestinal tract symptoms, and future research should concentrate on validating existing diagnostic criteria or developing more accurate ways of predicting a diagnosis of IBS without the need for investigation of theLower gastrointestinal tract.

Acupuncture for treatment of irritable bowel syndrome.

TLDR
It is still inconclusive whether acupuncture is more effective than sham acupuncture or other interventions for treating IBS, and as effective as other interventions used to treat irritable bowel syndrome.

Hypnotherapy for treatment of irritable bowel syndrome.

TLDR
The therapeutic effect of hypnotherapy was found to be superior to that of a waiting list control or usual medical management, for abdominal pain and composite primary IBS symptoms, in the short term in patients who fail standard medical therapy.

Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial

TLDR
Tegaserod is effective in treating overall IBS symptoms in patients with IBS-Mixed and IBS with constipation and the most frequent adverse events leading to study discontinuation in tegaserod-treated patients were diarrhea and abdominal pain.

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome.

  • M. CamilleriS. Mckinzie A. Zinsmeister
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2004

Herbal medicines for treatment of irritable bowel syndrome.

TLDR
Some herbal medicines may improve the symptoms of irritable bowel syndrome, however, positive findings from less rigorous trials should be interpreted with caution due to inadequate methodology, small sample sizes, and lack of confirming data.
...